Hypothesis
The use of Abiraterone 250 mg with food + prednisone, without LHRH analogs or blockers (ADT), achieves castration-level testosterone at 30 days in ≥80-90% of cases.
Age ≥18 years.
Histologically confirmed prostate adenocarcinoma.
Treated at Hospital Durand (Argentina) or Instituto Oncológico del Oriente Boliviano (Bolivia).
Indicated for hormonal intensification (high/very high risk candidates for RT, or mHSPC for doublet/triplet).
Hypersensitivity to ABI/prednisone; moderate-severe hepatic impairment; uncontrolled hypertension; refractory hypokalemia.
Concurrent therapy with strongly contraindicated/inducing drugs affecting ABI levels without possibility of adjustment.